WO1999025734A3 - Th2 CELL DEPLETION; COMPOSITIONS; METHODS - Google Patents

Th2 CELL DEPLETION; COMPOSITIONS; METHODS Download PDF

Info

Publication number
WO1999025734A3
WO1999025734A3 PCT/US1998/023240 US9823240W WO9925734A3 WO 1999025734 A3 WO1999025734 A3 WO 1999025734A3 US 9823240 W US9823240 W US 9823240W WO 9925734 A3 WO9925734 A3 WO 9925734A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
cell depletion
ccr8
binding
Prior art date
Application number
PCT/US1998/023240
Other languages
French (fr)
Other versions
WO1999025734A2 (en
Inventor
Hortensia Soto-Trejo
Joseph A Hetrick
Original Assignee
Schering Corp
Napolitano Monica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Napolitano Monica filed Critical Schering Corp
Priority to CA002309761A priority Critical patent/CA2309761A1/en
Priority to EP98957483A priority patent/EP1030865A2/en
Priority to JP2000521113A priority patent/JP2001523446A/en
Priority to AU13730/99A priority patent/AU1373099A/en
Publication of WO1999025734A2 publication Critical patent/WO1999025734A2/en
Publication of WO1999025734A3 publication Critical patent/WO1999025734A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Binding compositions which selectively bind to a marker specifically found on Th2 cells and various methods of use of the binding compositions are provided. In particular, the method makes use of fact that the CCR8 chemokine receptor is selectively expressed on the Th2 cell subset. Preferably, the binding composition is a monoclonal antibody specific for CCR8.
PCT/US1998/023240 1997-11-13 1998-11-12 Th2 CELL DEPLETION; COMPOSITIONS; METHODS WO1999025734A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002309761A CA2309761A1 (en) 1997-11-13 1998-11-12 Th2 cell depletion; compositions; methods
EP98957483A EP1030865A2 (en) 1997-11-13 1998-11-12 Th2 CELL DEPLETION; COMPOSITIONS; METHODS
JP2000521113A JP2001523446A (en) 1997-11-13 1998-11-12 Th2 cell depletion, compositions, methods
AU13730/99A AU1373099A (en) 1997-11-13 1998-11-12 Th2 cell depletion; compositions; methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6539297P 1997-11-13 1997-11-13
US60/065,392 1997-11-13

Publications (2)

Publication Number Publication Date
WO1999025734A2 WO1999025734A2 (en) 1999-05-27
WO1999025734A3 true WO1999025734A3 (en) 1999-07-15

Family

ID=22062409

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/023240 WO1999025734A2 (en) 1997-11-13 1998-11-12 Th2 CELL DEPLETION; COMPOSITIONS; METHODS

Country Status (7)

Country Link
EP (1) EP1030865A2 (en)
JP (1) JP2001523446A (en)
AR (1) AR016681A1 (en)
AU (1) AU1373099A (en)
CA (1) CA2309761A1 (en)
WO (1) WO1999025734A2 (en)
ZA (1) ZA9810371B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6416954B1 (en) * 1999-02-08 2002-07-09 Schering Corporation Modulating Th2 cell levels via vMIP-I/CCR8 interaction
WO2001058484A2 (en) * 2000-02-10 2001-08-16 Schering Corporation Novel uses of mammalian ccr8 receptors and related reagents
US6762341B2 (en) 2000-02-10 2004-07-13 Schering Corporation Uses of mammalian CCR8 receptors and related reagents
WO2003096020A2 (en) * 2002-05-13 2003-11-20 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with chemokine receptor 8 (ccr8)
WO2007044756A2 (en) * 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8
WO2014082993A2 (en) * 2012-11-30 2014-06-05 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the down-regulation of the th2 response
JP7358047B2 (en) * 2016-05-16 2023-10-10 チェックマブ エス．アール．エル． Markers selectively deregulated in tumor-infiltrating regulatory T cells
US20220064312A1 (en) 2018-12-27 2022-03-03 Shionogi & Co., Ltd. Novel Anti-CCR8 Antibody
US11692038B2 (en) 2020-02-14 2023-07-04 Gilead Sciences, Inc. Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
WO2023219147A1 (en) * 2022-05-13 2023-11-16 塩野義製薬株式会社 Novel anti-ccr8 antibodies for detecting ccr8

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0025722A2 (en) * 1979-09-18 1981-03-25 Ortho Pharmaceutical Corporation Monoclonal antibody to human cytotoxic and suppressor T cells, and method of preparing it
WO1997003695A1 (en) * 1995-07-21 1997-02-06 Applied Research Systems Ars Holding N.V. Methods for detecting, identifying, isolating, and selectively labelling and targeting th1 lymphocytes by means of the lag-3 protein
WO1997046677A1 (en) * 1996-06-05 1997-12-11 Bml, Inc. PROTEIN SPECIFIC TO HUMAN Th2, GENE (B19) ENCODING THE SAME, AND TRANSFORMANT, RECOMBINANT VECTOR AND MONOCLONAL ANTIBODY RELATING THERETO

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0025722A2 (en) * 1979-09-18 1981-03-25 Ortho Pharmaceutical Corporation Monoclonal antibody to human cytotoxic and suppressor T cells, and method of preparing it
WO1997003695A1 (en) * 1995-07-21 1997-02-06 Applied Research Systems Ars Holding N.V. Methods for detecting, identifying, isolating, and selectively labelling and targeting th1 lymphocytes by means of the lag-3 protein
WO1997046677A1 (en) * 1996-06-05 1997-12-11 Bml, Inc. PROTEIN SPECIFIC TO HUMAN Th2, GENE (B19) ENCODING THE SAME, AND TRANSFORMANT, RECOMBINANT VECTOR AND MONOCLONAL ANTIBODY RELATING THERETO

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
A. ZINGONI ET AL.,: "The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells", JOURNAL OF IMMUNOLOGY, vol. 161, no. 2, 15 July 1998 (1998-07-15), pages 547 - 551, XP002102438 *
BERNARDINI ET AL: "Identification of the CC chemokines TARC and macrophage inflammatory protein-1 beta as novel functional ligands for the CCR8 receptor", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 28, no. 2, February 1998 (1998-02-01), pages 582 - 588, XP002092743 *
D. D'AMBROSIO ET AL.,: "Selective upregulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells", JOURNAL OF IMMUNOLOGY, vol. 161, no. 10, 15 November 1998 (1998-11-15), pages 5111 - 5115, XP002102441 *
DATABASE WPI Section Ch Week 9804, Derwent World Patents Index; Class B04, AN 98-042185, XP002102442 *
HORUK ET AL: "The CC chemokine I-309 inhibits CCR8-dependent infection by diverse HIV-1 strains", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 1, 2 January 1998 (1998-01-02), pages 386 - 391, XP002092742 *
I. GOYA ET AL.,: "Identification of CCR8 as the specific receptor for the human beta-chemokine I-309: cloning and molecular characterization of murine CCR8 as the receptor for TCA-3", THE JOURNAL OF IMMUNOLOGY, vol. 160, 1998, pages 1975 - 1981, XP002102439 *
SOZZANI ET AL.: "The viral chemokine macrophage inflammatory protein-II is a selective Th2 chemoattractant", BLOOD, vol. 92, no. 11, 1 December 1998 (1998-12-01), pages 4036 - 4039, XP002102440 *
TIFFANY ET AL: "Identification of CCR8: a human monocyte and thymus receptor for the CC chemokine I-309", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 186, no. 1, 7 July 1997 (1997-07-07), pages 165 - 170, XP002092538 *

Also Published As

Publication number Publication date
WO1999025734A2 (en) 1999-05-27
CA2309761A1 (en) 1999-05-27
AU1373099A (en) 1999-06-07
ZA9810371B (en) 1999-08-30
AR016681A1 (en) 2001-07-25
JP2001523446A (en) 2001-11-27
EP1030865A2 (en) 2000-08-30

Similar Documents

Publication Publication Date Title
AU7625998A (en) methods, kits and compositions for suppressing the binding of detectable probe s to non-target sequences in hybridization assays
AU2821195A (en) Cross-reacting monoclonal antibodies specific for e-selectin and p-selectin
EP1071460A4 (en) INTERNALIZING ErbB2 ANTIBODIES
WO1999042077A3 (en) Compositions and methods for regulating lymphocyte activation
CA2259421A1 (en) Labelling and selection of molecules
AU4639396A (en) Cytokine designated lerk-7
EP1881064A3 (en) HCV-Anti-core monoclonal antibodies
WO1997046589A3 (en) Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
AU3927597A (en) Covered sample well for use in nucleic acid assays and immunoassays
IL142905A0 (en) Functional antagonists of hedgehog activity
WO1999025734A3 (en) Th2 CELL DEPLETION; COMPOSITIONS; METHODS
EP0199801A4 (en) Methods for protein binding enzyme complementation assays.
AU7576898A (en) Composition useful for hydrocarbon conversion process and preparation thereof
WO1998009647A3 (en) Cyanidin compositions and therapeutic and diagnostic uses therefor
EP0217992A3 (en) Lysing or blocking unwanted cells
WO2005028497A3 (en) Receptor binding peptides derived from the sars s protein
AU9508998A (en) Methods and compositions for binding hematopoietic stem cells
WO2004020597A3 (en) Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
WO1995007466A3 (en) Biotin-analog conjugated antibodies for positive cell selection and release
CA2170606A1 (en) Type i angiotensin ii receptor specific monoclonal antibodies and hybridomas
WO1998035550A3 (en) Insect ecdysteroid receptors
WO2001085779A3 (en) Protein complexes and assays for screening anti-cancer agents
AU4375493A (en) Isolated protein receptors, antibodies which bind thereto, nucleic acid sequence coding therefor, and uses thereof
EP0453097A3 (en) Zusammensetzung enthaltend zumindest zwei verschiedene Antikörper oder deren Fragmente
AU2547995A (en) Monoclonal antibody specific for vascular endothelial cell antigen endoglyx-1, the antigen itself, and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CZ EE GD GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CZ EE GD GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 521113

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2309761

Country of ref document: CA

Ref country code: CA

Ref document number: 2309761

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/004667

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998957483

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998957483

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998957483

Country of ref document: EP